Product Description: Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.
CAS Number: 2069959-72-2
Molecular Weight: N/A
Compound Purity: 99.58
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: CD3